https://www.youtube.com/watch?v=7pA54ImDLAk&t=12s&ab_channel=InternationalHuntingtonAssociation Svein Olaf Olsen, President of the International Huntington Association, interviews Maaike, an example of strength and hope, with a moving story.
Roche/ Genentech announce that Phase II GENERATION HD2 study is now open. This is great news for the international community since it is planned to run in 15 countries (Argentina,
Novartis shared today the difficult news that they are stopping the VIBRANT-HD study of Branaplam, after some participants devoloping side effects. Read the full Novartis letter Even if this news
IHA interviews Robert Pacifici from CHDI IHA interviews Robert Pacifici from CHDI IHA interviews Robert Pacifici from CHDI IHA interviews Robert Pacifici from CHDI Svein Olaf Olsen, President of the
International Huntington Association has received a very generous donation. A Norwegian donor is behind the donation. He wishes to remain anonymous. The money is earmarked for a new position at
Have you heard of the Joyvest by Lyckna? It’s an activity vest that plays music when you move! Carina, from the Huntington’s Disease Association (RHS) in Sweden makes a demonstration.
A Message to the Huntington’s Disease Community from uniQure Dear Huntington’s Disease Community Members, This morning, uniQure issued a press release which included an update on our clinical trial ofAMT-130
September 20, 2022 at 7:30 AM EDT PDF Version Single doses of WVE-003 appear generally safe and well-tolerated CSF mutant huntingtin (mHTT) protein was reduced following single doses of 30
~ Treatment generally well-tolerated with no significant safety issues related to AMT-130 in treated patients through one year of follow-up ~ ~ A mean reduction of 53.8% of mutant HTT
ANNEXON BIOSCIENCES REPORTS PHASE 2 CLINICAL TRIAL RESULTS DEMONSTRATING UPSTREAM CLASSICAL COMPLEMENT INHIBITION ASSOCIATED WITH CLINICAL BENEFIT IN HUNTINGTON’S DISEASE On June 7, Annexon, that is a clinical-stage biopharmaceutical company
Join our campaign for Rare Disease Day! February 28th is Rare Disease Day, where the rare community comes together, finds support and raises awareness for rare diseases across the globe
https://www.youtube.com/watch?v=7pA54ImDLAk&t=12s&ab_channel=InternationalHuntingtonAssociation Svein Olaf Olsen, President of the International Huntington Association, interviews Maaike, an example of strength and hope, with a moving story.
Roche/ Genentech announce that Phase II GENERATION HD2 study is now open. This is great news for the international community since it is planned to run in 15 countries (Argentina,
Novartis shared today the difficult news that they are stopping the VIBRANT-HD study of Branaplam, after some participants devoloping side effects. Read the full Novartis letter Even if this news
IHA interviews Robert Pacifici from CHDI IHA interviews Robert Pacifici from CHDI IHA interviews Robert Pacifici from CHDI IHA interviews Robert Pacifici from CHDI Svein Olaf Olsen, President of the
International Huntington Association has received a very generous donation. A Norwegian donor is behind the donation. He wishes to remain anonymous. The money is earmarked for a new position at
Have you heard of the Joyvest by Lyckna? It’s an activity vest that plays music when you move! Carina, from the Huntington’s Disease Association (RHS) in Sweden makes a demonstration.
A Message to the Huntington’s Disease Community from uniQure Dear Huntington’s Disease Community Members, This morning, uniQure issued a press release which included an update on our clinical trial ofAMT-130
September 20, 2022 at 7:30 AM EDT PDF Version Single doses of WVE-003 appear generally safe and well-tolerated CSF mutant huntingtin (mHTT) protein was reduced following single doses of 30
~ Treatment generally well-tolerated with no significant safety issues related to AMT-130 in treated patients through one year of follow-up ~ ~ A mean reduction of 53.8% of mutant HTT
French 
English 
Arabic 
Bulgarian 
Chinese 
Czech 
Danish 
Dutch 
Estonian 
Finnish 
German 
Greek 
Hungarian 
Indonesian 
Italian 
Japanese 
Latvian 
Lithuanian 
Polish 
Portuguese 
Romanian 
Russian 
Slovak 
Slovenian 
Spanish 
Swedish 
Turkish 
Ukrainian